ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1100 • ACR Convergence 2023

    A Comparison of Characteristics of Patients with Crystalline and Septic Arthritis Confirmed by Synovial Fluid Analysis: Towards the Development of a Diagnostic Rule

    Maria Salgado Guerrero1, Mariana Urquiaga1, Nishah Panchani2 and Angelo Gaffo3, 1University of Alabama at Birmingham, Birmingham, AL, 2Tinsley Harrison Internal Medicine Residency Program, University of Alabama at Birmingham, Arlington, TX, 3Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, AL; Birmingham VA Medical Center, Birmingham, AL

    Background/Purpose: Distinguishing crystalline from septic arthritis is a common challenge in patients admitted with acute joint inflammation. Arthrocentesis for synovial fluid analysis is considered the…
  • Abstract Number: 1128 • ACR Convergence 2023

    Refractory Inflammatory Ocular Pathology and Treatment with Janus Kinase Inhibitors. Multicenter Study and Literature Review

    Carmen Lasa-Teja1, Lara Sanchez-Bilbao2, Jose Luis Martin-Varillas3, Vanesa Calvo Río4, José Luis Álvarez-Vega5, Emma Beltran-Catalan6, María del Mar Esteban-Ortega7, Santiago Muñoz7, Olga Maiz8, Ignacio Torre-Salaberri9, Ana Urruticoechea10, Elia Valls-Pascual11, Raúl Veroz12, Carmen Alvarez Reguera13, Rosalía Demetrio13 and Ricardo Blanco14, 1Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology Group, Santander, Spain, 2Hospital Universitario Marques de Valdecilla, Santander, Spain, 3Hospital de Laredo, Laredo, Spain, 4Valdecilla Hospital, Santander, Spain, 5Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain, 6HOSPITAL DEL MAR, Barcelona, Spain, 7Hospital Infanta Sofia, Madrid, Spain, 8Hospital Universitario de Donostia. San Sebastián, Spain., Donosti, Spain, 9Hospital Universitario de Basurto, Bilbao, Spain, 10Hospital Can Misses, Ibiza, Spain, 11Hospital Universitario Doctor Peset. Alicante, Spain., Valencia, Spain, 12Hospital de Mérida, Mérida. Spain., Mérida, Spain, 13Hospital Universitario Marqués de Valdecilla, Santander, Spain, 14Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

    Background/Purpose: Inflammatory ocular pathology (IOP) includes internal (uveitis) and external [mainly ocular surface pathology such as epi/scleritis and peripheral ulcerative keratitis (PUK)] involvement. IOP may…
  • Abstract Number: 1129 • ACR Convergence 2023

    Accuracy and Performance Characteristics of Administrative Codes for the Diagnosis of Autoinflammatory Syndromes: A Discovery and Validation Study

    Saeyun Lee1, Sujin Kim2, Suzanne Segerstrom2, Polly Ferguson1 and Aleksander Lenert3, 1University of Iowa Carver College of Medicine, Iowa City, IA, 2University of Kentucky, Lexington, KY, 3University of Iowa, Iowa City, IA

    Background/Purpose: Autoinflammatory syndromes (AIS), a group of rare rheumatic diseases driven by the innate immune system, remain understudied due to the lack of prospective cohorts.…
  • Abstract Number: 1132 • ACR Convergence 2023

    Preclinical Profiles of FZ007-119, a Highly Potent and Selective Tyk2 Inhibitor, for the Treatment of Immune Mediated Inflammatory Diseases

    Wenhe Zhong, Jielian Lu, Dong Chen, Shiqun Zhang and Daiguo Deng, Guangzhou Fermion Technology Co., LTD, Guangzhou, China

    Background/Purpose: Tyrosine Kinase 2 (TYK2) is a signaling protein within the Janus kinase (JAK) family. It plays a crucial role in transmitting signals from pro-inflammatory…
  • Abstract Number: 1120 • ACR Convergence 2023

    Target Serum Urate Levels, Recurrent Gout Flare Rates, and Gout-Primary Hospitalizations: Nationwide Prospective Cohort Study of 3,613 Gout Patients

    Natalie McCormick1, Chio Yokose2, Gregory Challener1, Amit Joshi3, Sruthi Tanikella1 and Hyon K. Choi4, 1Massachusetts General Hospital, Boston, MA, 2Massachusetts General Hospital, Waltham, MA, 3Channing Division of Network Medicine, Boston, MA, 4Massachusetts General Hospital and Harvard Medical School, Lexington, MA

    Background/Purpose: Despite rheumatology guidelines' emphasis on treat-to-target-serum-urate (SU) levels (<6 or <5 mg/dL, urate crystal sub-saturation points), this pathophysiology-based recommendation is not accepted in primary…
  • Abstract Number: 1093 • ACR Convergence 2023

    Development of Adaptive Immunity Against Different SARS-CoV-2 Variants over the Course of Three COVID-19 Vaccinations in Patients with Inflammatory Rheumatic Diseases

    Liam Huppke1, Paul Wratil2, Marie Bischof2, Stefan Wolfrum1, Fabian Ullrich1, Delila Singh1, Julia Lichtnekert1, Lea Grümme1, Christina Gebhardt1, Klaus Krüger3, Franziska Wiesent4, Alla Skapenko1, Oliver Keppler5 and Hendrik Schulze-Koops6, 1Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, University of Munich, Munich, Germany, 2Max von Pettenkofer Institute & Gene Centre, Virology, National Reference Centre for Retroviruses, LMU Munich, Munich, Germany, 3Praxiszentrum St. Bonifatius, Munich, Germany, 4Endokrinologikum München, Munich, Germany, 5Max von Pettenkofer Institute & Gene Centre, Virology, National Reference Centre for Retroviruses, LMU München, Munich, Germany, 6Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, Ludwig-Maximilians–University Munich, Munich, Germany

    Background/Purpose: Even though individuals with inflammatory rheumatic diseases (IRDs) were excluded from the SARS-CoV-2 vaccine trails, studies have shown that these individuals at risk of…
  • Abstract Number: 1136 • ACR Convergence 2023

    Challenges in Diagnosing VEXAS Syndrome: Delayed Diagnosis, Misdiagnosis, and Associations with Specific Gene Mutations

    Paula García Escudero1, Marta López i Gómez2, Marta López Maraver3, PALOMA VELA4, María Rodríguez Laguna5, carolina Merino6, Ana Victoria Orenes Vera7, Clara García Belando8, Diego Dios Santos9, Jose Alberto Miranda Filloy10, Francisco Javier Toyos Sáenz de Miera11, Alicia Garcia Dorta12, Ignacio Vázquez13, José Ángel Hernández Beriain14, MARIA ELVIRA DIEZ ALVAREZ15, Marta Ibáñez Martínez16, Beatriz Frade Sosa17, Judit Font Urgelles18, Meritxell Salles Lizarzaburu19, Elena Riera Alonso20, Ernesto Trallero Araguás21, Berta Magallanes López22, Joaquín Belzunegui Otano23, Carlos de Miguel Sánchez24, Zuriñe Ortiz de Zárate Caballero25 and Jaime Calvo Alén26, 1Hospital Universitario Araba, Bilbao, Spain, 2Hospital Universitario de Araba, Pamplona, Spain, 3Hospital Universitario de Araba, Vitoria, Spain, 4Rheumatology, Hospital General Universitario Alicante, Alicante, Spain, 5H. Clínico San Carlos, Madrid, Spain, 6Rheumatology Department Hospital Universitario Puerta de Hierro, Majadahonda (Madrid), Spain, 7H. Arnau de Vilanova, Valencia, Spain, 8Hospital Los Arcos del Mar Menor, Murcia, Spain, 9Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain, 10C. H. U. Lucus Augusti, Lugo, Spain, 11Hospital Virgen Macarena, Sevilla, Spain, 12Rheumatology Unit, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, 13H. U. Dr. Peset, Valencia, Spain, 14Rheumatology, Hospital Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain, 15Rheumatology, Hospital Universitario de León, León, Spain, 16C. A. U. de Salamanca, Salamanca, Spain, 17Hospital Clínic de Barcelona, Barcelona, Spain, 18Hospital Universitario Germans Trías i Pujol, Barcelona, Spain, 19C. H. de Manresa - Fundació Althaia, Barcelona, Spain, 20Hospital Universitario Mútua Terrassa, Barcelona, Spain, 21Department of Rheumatology, Hospital Universitario Vall d'Hebron, Barcelona, Spain, 22Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 23Hospital Universitario Donosti, Donosti, Spain, 24Hospital Universitario de Araba, Hematology, VItoria, Spain, 25Hospital Universitario de Araba, Internal Medicine, Vitoria, Spain, 26Hospital Universitario Araba, Vitoria, Spain

    Background/Purpose: The newly described VEXAS syndrome is a very heterogenous disease with rheumatologic and hematologic manifestations, caused by somatic mutations affecting UBA1 gene, that still…
  • Abstract Number: 1139 • ACR Convergence 2023

    From Skin to Bone Lesions: A Pioneer Study Unraveling the Underdiagnosis of SAPHO Syndrome in the Dominican Republic

    Leeany Maletta1, Diana Jimenez2 and Rosanna de Jesus3, 1UNIBE School of Medicine, San Antonio, TX, 2UNIBE School of Medicine, Miami, FL, 3Hospital General Plaza de la Salud, Distrito Nacional, Dominican Republic

    Background/Purpose: SAPHO syndrome is a rare chronic inflammatory condition that affects the skin and osteoarticular structures. Despite being first described over 30 years ago, it…
  • Abstract Number: 1137 • ACR Convergence 2023

    Association Between Nailfold Videocapillaroscopy Findings and sKL-6 Levels in Patients with Idiopathic Inflammatory Myopathies–Related Interstitial Lung Disease

    Cristiana Sieiro Santos1, Jose Luis Tandaipan2, Diego Castillo2, Laura Martínez Martínez2, Helena Codes2, Luis Sainz-Comas2, Berta Paula Magallares-Lopez3, Patricia Moya2, Anais Mariscal2, Hye Sang Park2, Ana Milena Millán Arciniegas2, César Díaz-Torné2, Ana Laíz Alonso2, Sandra Ros2, Susana Fernández2, Hector Corominas4, Elvira Díez Álvarez5 and Iván Castellvi2, 1Complejo Asistencial Universitario de León, León, Spain, 2Hospital de Santa Creu i Sant Pau, Barcelona, Spain, 3Department of Rheumatology, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain, 4Hospital Universitario Sant Pau, Rheumatology, Barcelona, Spain, 5CAULE, León, Spain

    Background/Purpose: Interstitial lung disease (ILD) is a frequent pulmonary manifestation in idiopathic inflammatory myopathies (IIM) (IIM-ILD) and considerably influences morbidity and mortality. Krebs von den…
  • Abstract Number: 1138 • ACR Convergence 2023

    Nailfold Capillaroscopy Findings in Patients with Idiopathic Inflammatory Myopathies and Its Association to Autoantibodies

    Cristiana Sieiro Santos1, Jose Luis Tandaipan2, Anais Mariscal2, Luis Sainz-Comas2, Helena Codes2, Patricia Moya2, Berta Paula Magallares-Lopez3, Laura Martínez Martínez2, Ana Milena Millán Arciniegas2, Hye Sang Park2, César Díaz-Torné2, Ana Laíz Alonso2, Susana Fernández2, Sandra Ros2, Hector Corominas4, Elvira Díez Álvarez5 and Iván Castellvi2, 1Complejo Asistencial Universitario de León, León, Spain, 2Hospital de Santa Creu i Sant Pau, Barcelona, Spain, 3Department of Rheumatology, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain, 4Hospital Universitario Sant Pau, Rheumatology, Barcelona, Spain, 5CAULE, León, Spain

    Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of acquired muscle diseases, which have distinct clinical, pathological and histological features. Autoantibodies are clinically useful…
  • Abstract Number: 1123 • ACR Convergence 2023

    Real-world Trends in the Use of Immunomodulation as Co-therapy to Pegloticase: Claims-based Findings Since 2016

    John Botson1, Qianhong Fu2, Kaiding Zhu2, Lissa Padnick-Silver2 and Brian LaMoreaux2, 1Orthopedic Physicians Alaska, Anchorage, AK, 2Horizon Therapeutics, Deerfield, IL

    Background/Purpose: Pegloticase can treat uncontrolled gout but anti-drug antibodies limit urate-lowering response and put patients at risk for infusion reactions (IRs).1, 2 The first case…
  • Abstract Number: 1144 • ACR Convergence 2023

    Deucravacitinib in Plaque Psoriasis: Maintenance of Response over 3 Years

    Bruce Strober1, Howard Sofen2, Shinichi Imafuku3, Carle Paul4, Melinda Gooderham5, Lynda Spelman6, Seong Jun Seo7, Thierry Passeron8, Renata M. Kisa9, Victoria Berger9, Eleni Vritzali10, Kim Hoyt9, Matthew J. Colombo9, Subhashis Banerjee9, Matthias Augustin11, Linda Stein Gold12, Andrew Alexis13, Diamant Thaçi14, Andrew Blauvelt15 and Mark Lebwohl16, 1Yale University, New Haven, CT, 2University of California Los Angeles School of Medicine and Dermatology Research Associates, Los Angeles, CA, 3Fukuoka University Faculty of Medicine, Fukuoka, Japan, 4Toulouse University and CHU, Toulouse, France, 5SKiN Centre for Dermatology, Ontario, Canada, 6Veracity Clinical Research, Brisbane, Australia, 7Chung-Ang University Hospital, Seoul, South Korea, 8Université Côte d’Azur, University Hospital of Nice, Nice, France, 9Bristol Myers Squibb, Princeton, NJ, 10Bayer, Sissach, Switzerland, 11Institute of Health Care Research in Dermatology and Nursing, Hamburg, Germany, 12Henry Ford Health System, MI, 13Weill Cornell Medicine, New York, NY, 14Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany, 15Oregon Medical Research Center, Portland, OR, 16Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY

    Background/Purpose: Deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved in multiple countries for the treatment of adults with plaque psoriasis. Deucravacitinib…
  • Abstract Number: 1142 • ACR Convergence 2023

    A Retrospective Analysis of Radiographic and Serologic Findings in Patients with Scleroderma and Interstitial Lung Disease

    Nikita Jhawar, Claire Wilson, Andy Abril, Li Zhuo and Yaohua Ma, Mayo Clinic, Jacksonville, FL

    Background/Purpose: Connective tissue diseases such as scleroderma are frequently associated with interstitial lung disease (ILD). Detection of autoantibodies is crucial in characterizing disease phenotypes, but…
  • Abstract Number: 1147 • ACR Convergence 2023

    Blood-Based Biomarkers of Inflammation and Tissue Remodeling Can Discriminate Between Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis and Are Associated with Hand Function

    Helena Port I Linares1, Birte Coppers2, Sara Bayat2, Godonou Elie-Tino2, Larissa Valor-Mendez2, David Simon2, Filippo Fagni2, Giulia Corte2, Anne-Christine Bay-Jensen3, Koray Tascilar2, Axel Hueber4, Verena Schoenau2, Michael Sticherling5, Simon Heinrich6, Daniela Bohr2, Georg Schett7, Arnd Kleyer8, Sigrid Leyendecker6, Signe Holm Nielsen3 and Anna-Maria Liphardt9, 1Nordic Bioscience A/S / University of Copenhagen, Copenhagen, Denmark, 2Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg & Universitätsklinikum Erlangen, Department of Internal Medicine 3 - Rheumatology and Immunology / Deutsches Zentrum Immuntherapie, Erlangen, Germany, 3Nordic Bioscience, Herlev, Denmark, 4Division of Rheumatology, Klinikum Nürnberg, Paracelsus Medical University / Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg & Universitätsklinikum Erlangen, Department of Internal Medicine 3 - Rheumatology and Immunology, Nürnberg, Germany, 5Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg & Universitätsklinikum Erlangen, Department of Dermatology, Erlangen, Germany, 6Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Institute of Applied Dynamics, Erlangen, Germany, 7Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, 8University Hospital Erlangen, Erlangen, Germany, 9Friedrich-Alexander-University Erlangen-Nuremberg, Internal Medicine 3 - Rheumatology and Immunology, University Hospital Erlangen, Erlangen, Germany

    Background/Purpose: Inflammatory musculoskeletal diseases including rheumatoid arthritis (RA) and psoriatic arthritis (PsA) are characterized by physical function impairment due to progressive inflammatory and structural changes.…
  • Abstract Number: 1148 • ACR Convergence 2023

    A Comparative Study of Clinical Phenotype in Relation to NOD2 Sub-genotypes in Yao Syndrome

    Ashmia Saif1, Hafsa Nomani2, Frank Hwang2, Jie Yang2 and Qingping Yao2, 1Stony Brook University Hospital, Syosset, NY, 2Stony Brook University, Stony Brook, NY

    Background/Purpose: Yao syndrome (YAOS, OMIM 617321) is formerly designated NOD2-associated autoinflammatory disease. A spectrum of NOD2 mutations have been associated with this disease. Most patients…
  • « Previous Page
  • 1
  • …
  • 315
  • 316
  • 317
  • 318
  • 319
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology